USANA Health Sciences, Inc.

USANA Health Sciences, Inc.

USNANYSE / NASDAQConsumer DefensiveSmall cap

$12.94-$0.22 (-1.7%)

Last close · Data as of Nov 20, 2026

Market cap
$334.7M
P/E
31.1x
EV / EBITDA
2.4x
Revenue
$925.3M
Net margin
1.2%
ROCE
8.3%

-30.7% over the last year

USANA Health Sciences, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-12.1%
3M
-1.8%
6M
-28.7%
1Y
-30.7%
5Y
-87.3%

52-week range

Day change -$0.22 (-1.7%) from $13 to $13 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in USNA, bought on each weekday since 2021.

News & filings

What USANA Health Sciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was 50.4 times interest costs.

Concerns (1)

  • Net profit fell 46.3% a year over three years.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer.

Read moreShow less

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company was founded in 1992 and is headquartered in Salt Lake City, Utah.

Sector
Consumer Defensive
Shares outstanding
18.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$334.7M
P/E
31.1x
P/B
0.6x
EV / EBITDA
2.4x
EV / Sales
0.2x
P/S
0.4x
52-week high
$23.24
52-week low
$12.73

Profitability

Operating margin
5.5%
Net margin
1.2%
EBITDA margin
8.9%
ROE
2.0%
ROCE
8.3%
ROIC
6.2%
ROA
1.4%
Asset turnover
1.25

Growth

Revenue
$925.3M
Revenue growth, 1Y
8.3%
Revenue CAGR, 3Y
-2.5%
Net profit growth, 1Y
-74.4%
Free cash flow
$8.5M

Solvency

Current ratio
2.24
Debt / Equity
0.04
Debt / Assets
0.03
CFO / Net profit
2.08
Cash / Market cap
47.3%

Where the revenue went

Of every $100 of FY2025 revenue, $1 was left as net income.

USANA Health Sciences, Inc. income statement flow, FY2025
USANA Health Sciences, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$200.8M
RevenueGross profit$724.4M
Gross profitSelling, general and administrative$337.4M
Gross profitOther operating expenses$336.2M
Gross profitOperating income$50.9M
Operating incomePretax income$41.5M
Operating incomeInterest and other expense$9.3M
Pretax incomeTax and other$30.8M
Pretax incomeNet income$10.8M

Revenue and net profit

Revenue grew 8.3% in FY2025; net profit is the dashed line.

USANA Health Sciences, Inc. revenue and net profit by fiscal year
USANA Health Sciences, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$998.6M$69.3M
FY2023$921.0M$63.8M
FY2024$854.5M$42.0M
FY2025$925.3M$10.8M

Cash flows

FY2025: $22.3M from operations, $8.5M free after investment (dashed).

USANA Health Sciences, Inc. operating and free cash flow by fiscal year
USANA Health Sciences, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$103.9M$93.5M
FY2023$70.6M$56.1M
FY2024$61.0M$50.9M
FY2025$22.3M$8.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$925.3M+8.3%1Y
EBITDA
$82.1M-17.0%1Y
Net profit
$10.8M-74.4%1Y
Cash from operations
$22.3M-63.4%1Y
Free cash flow
$8.5M-83.3%1Y
Revenue CAGR, 3Y
-2.5%
Net profit CAGR, 3Y
-46.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$925.3M$82.1M$10.8M$8.5M2.0%+8.3%-74.4%

Monthly returns

Month-by-month returns of USNA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$742.9M
Liabilities$156.6M
Equity$586.3M
Paid-in capital$83.5M
Retained earnings$465.7M
Minority interest$53.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Consumer Defensive companies placed by value, growth and quality; USNA highlighted.

P/E against peers

USNA trades at 31.1x earnings against a peer median of 17.7x (a 75% premium).

  1. USANA Health Sciences, Inc. (this company)31.1x

Not shown (no positive earnings and no EV / Sales): The Honest Company, Inc., MGP Ingredients, Inc., B&G Foods, Inc., Alico, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
USANA Health Sciences, Inc.USNAthis companyP/E ↑ premium$334.7M31.1x0.6x2.0%2.4x
The Honest Company, Inc.HNST$362.2M-23.1x2.1x-9.2%-60.3x
Lifeway Foods, Inc.LWAY$355.6M25.7x4.1x16.1%14.8x
MGP Ingredients, Inc.MGPI$347.7M-3.2x0.5x-15.0%-8.6x
Nature's Sunshine Products, Inc.NATR$346.1M17.7x2.1x12.1%6.2x
B&G Foods, Inc.BGS$320.6M—0.7x-9.6%12.0x
European Wax Center, Inc.EWCZ$319.1M36.8x4.0x11.0%9.9x
Alico, Inc.ALCO$299.8M-2.0x2.9x-143.0%-78.1x
Franklin Covey Co.FC$269.7M87.9x4.0x4.6%15.2x
Peer median—17.7x2.5x-2.3%8.0x

Year-to-date ROI

USNA since 1 January, against earlier years.

Historical volatility

USNA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

USANA Health Sciences, Inc. operating margin by fiscal year
USANA Health Sciences, Inc. operating margin by fiscal year
DateOperating margin
FY202210.8%
FY202310.1%
FY20247.8%
FY20255.5%
LineFY2025
Cost of revenueCost Of Revenue$200.8M
Gross profitGross Profit$724.4M
Operating expensesOperating Expense$673.5M
Other operating expensesOther Operating Expenses$336.2M
Total expensesTotal Expenses$874.4M
Pretax incomePretax Income$41.5M

Learn while you research

Academy chapters picked for USANA Health Sciences, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 31.1, learn when high multiples are justified.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Cyclical vs Defensive StocksConsumer staples behave defensively across the business cycle.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →